TLX250-CDX | Friends of Cancer Research

You are here

TLX250-CDX

Sponsor: 
Telix Pharmaceuticals
Indication: 
Renal cancer imaging product
Category: 
Year: 
2020
Date: 
Jul 1st
FDA Status: 
Designation Granted